EMA Refused: Kizfizo (temozolomide) — ORPHELIA Pharma

View source ↗

Summary

The EMA refused marketing authorization for Kizfizo (temozolomide) for neuroblastoma, in an application from ORPHELIA Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Kizfizo (temozolomide)

Snippet

Status: Refused. Therapeutic area: Neuroblastoma. MAH: ORPHELIA Pharma. Decision date: 02/05/2025